13F Pro

ARDXARDELYX, INC.(ARDX)Stock Analysis

AI analysis on 2,800+ stocks →
Healthcare →Nasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1437402ARDX stock profile & AI dashboard →

13F Pro Quality Score

35.3/100

Rank #2,153 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

94.1/100

Profitability

13.3/100

Balance Sheet

11.7/100

Earnings Quality

30.0/100

Free Cash Flow

12.5/100

Institutional Flow

61.2/100

Revenue Scale

32.8/100

Dilution Risk

14.9/100

ARDX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ARDELYX, INC. (ARDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARDX at 35.3/100 on a 32-signal composite quality model, placing it at rank #2,153 of 2,879 stocks — the bottom half of the AI-ranked universe. ARDX scores in the top quartile across revenue growth (94.1). Areas of concern include balance sheet strength (11.7) and free cash flow (12.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ARDELYX, INC. reports quarterly revenue of $94.5M, net income of $-37.6M, free cash flow of $-32.3M. Top institutional holders of ARDX by reported 13-F value include BlackRock,, MILLENNIUM MANAGEMENT, STATE STREET, based on the most recent SEC filings. ARDX trades on the Nasdaq exchange and files with the SEC under CIK 1437402. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARDELYX, INC. directly from SEC EDGAR.

✦

Fun facts about ARDELYX, INC.

Quirks, history, and lore behind ARDX — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A small-cap biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on gastrointestinal and cardiorenal diseases.
  • 2
    The Numbers
    Revenue in the range of tens of millions of dollars annually — classic early-commercial-stage biotech — with a market cap that has swung wildly on FDA decisions.
  • 3
    The History
    Founded in the early 2000s, the company spent over a decade developing drugs that work right inside the gut lining, targeting ion transporters rather than the usual molecular suspects.
  • 4
    The Secret
    Its science centers on blocking a specific sodium-hydrogen exchanger in the intestine — a mechanism most pharma companies completely ignored — to manage chronic kidney disease complications.
  • 5
    The Lore
    Its lead approved drug, tenapanor, treats hyperphosphatemia in dialysis patients — a mouthful of a condition that affects millions and had very few good options.
  • 6
    The Giveaway
    Ticker ARDX, drug named XPHOZAH — if you know that tenapanor finally won FDA approval after a bumpy road, you've been watching this kidney-focused biotech very closely.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$94.5M

Net Income

Q1 2026

$-37.6M

Free Cash Flow

Q1 2026

$-32.3M

D/E Ratio

Q1 2026

1.37

Get alerted when ARDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ARDELYX, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of ARDX

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARDX on your watchlist

Track score changes the day ARDELYX, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

META

Meta

13F Pro HomeView PricingFeatures

Is ARDX a good stock to buy?

13F Pro's AI-powered analysis of ARDELYX, INC. (ARDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARDX are available on the ARDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ARDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ARDELYX, INC.'s investment landscape.